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ABSTRACT
Purpose of review: Here, we identify shortcomings of standard compartment-based mathematical models of cancer
stem-cells, and propose a continuous formalism which includes the tumor microenvironment.
Recent findings: Stem-cell models of tumor growth have provided explanations for various phenomena in oncology including,
metastasis, drug- and radio-resistance, and functional heterogeneity in the face of genetic homogeneity. While some of
the newer models allow for plasticity, or de-differentiation, there is no consensus on the mechanisms driving this. Recent
experimental evidence suggests that tumor microenvironment factors like hypoxia, acidosis and nutrient deprivation have
causative roles.
Summary: To settle the dissonance between the mounting experimental evidence surrounding the effects of the microenviron-
ment on tumor stemness, We propose a continuous mathematical model where we model microenvironmental perturbations
like forces, which then shape the distribution of stemness within the tumor. We propose methods by which to systematically
measure and charaterize these forces, and show results of a simple experiment which support our claims.
Introduction
Although posited to exist over forty years ago1, cancer stem cells (CSCs) were first identified in 1997 by Bonnet and Dick in
leukemia2. Since this discovery, CSCs have been shown to exist in many solid tumor types, including colon3, brain4, breast5
and melanoma6. The cancer stem cell hypothesis (CSCH) states that each tumor is composed of a cellular hierarchy, at the top
of which is a population of ‘stem cells’ able to self-renew and give rise to the entire diversity of cells within the tumor. The
alternate, proliferative hypothesis suggests instead that each cell in the tumor has some low level of clonogenic potential, and
proliferation is driven by stochastic genetic alterations. These two models are schematised in Figure 1. The CSCH provides a
framework by which to understand many different aspects of cancer progression that the proliferative hypothesis cannot explain,
including: functional heterogeneity despite identical genetic states7,8; resistance to chemotherapy9–11 and radiotherapy12–14;
recurrence15; and metastasis16. However, the CSCH has been the subject of continual debate and modification in an attempt to
maintain compatibility with experimental observations. Most importantly, there is still no consensus as to how to identify a
CSC17. The most accepted paradigm is the use of specific cell surface markers for enrichment with propagation in specific
growth conditions and functional characterization with the clonogenic or sphere-forming assay and tumorigenic potential18.
Adding to the challenge, the number of ‘stem cell markers’ is legion, and the meaning19, not to mention permanence20, of each
is itself a source of ongoing debate.
While the CSCH has been able to explain many important aspects of cancer that the standard proliferative hypothesis has
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Figure 1. The two competing models of tumor growth regarding replicative and tumor forming potential. Left: the
hierarchical, or cancer stem cell, model in which only a subset of cells, the putative cancer stem cells, or Tumor Initiating Cells
(TICs), have the ability to proliferate indefinitely and can recapitulate the entire tumor, while all others are doomed to
differentiation into Transit Amplifying Cells (TACs) and eventual Terminal Differentiation (TD) and then death; and, Right:
The standard proliferative model, in which each cell has the same ability, with low probability, to form tumors. We represent
clonogenicity on the bottom of each panel where, on the left the red box means that the TICs have high probability and all
others have none, and on the right that all cells have equal, low clonogenic potential.
not, the arguments about its specific form continue to plague the cancer research community. In each rigorous formulation of
this model, experimental data differs, and does not fit the model with the expected precision21. In each subsequent iteration,
small adjustments to the standard hierarchical stem cell model are made. Recently, plasticity has been added to the model22,23,
by allowing transient amplifying cells (TACs) to dedifferentiate into stem cells to account for the experimental observations
of such transformations appearing to occur randomly24, or in response to radiation treatment25 and hypoxia26,27. While
these modifications represent steps forward in our quest to rigorously describe, and thereby understand, cancer, they are also
modifications of a model that may not be able to wholly capture the dynamics of this enigmatic disease (for an excellent review
of mathematical models of the CSCH, see Michor28). This sort of growing dissonance is not new in science; indeed, it seems to
be a conserved motif. Many examples exist where a model, like the celestial spheres in astronomy, is incrementally modified to
encompass data that were not available or considered when the model was conceived. The model can become increasingly
unwieldy until a new, simpler model can be postulated - as Newton’s laws explained Kepler’s observed patterns - whereupon,
the cycle begins anew.
We submit that in cancer research we find ourselves in a similar situation concerning the CSCH, and that to make further
progress, we must tear down the standard hierarchical architecture of the CSCH and recast it entirely. Therefore, we present a
novel model of cancer cell differentiation that does not take the standard compartmental form. We instead posit a continuum
model of differentiation and clonogenic state, mathematically similar to those of Hoffman et al.29 and Doumic et al.30, but
composed of cells whose behavior can change in response to environmental factors, which we model as ‘forces’. This model
allows for integration of the proliferative model and the CSCH and has the potential to reconcile previous issues over surface
markers, which themselves have continuous expression values, as the distinction between ‘stem’ or ‘non-stem’ cells is no
longer requisite. The model also provides a new way to define a tumor’s cellular composition and progression as a dynamic
distribution, and is supported by a number of recent biological observations10,25, 26, 31–37 into a single modeling framework.
Existing modifications to the canonical model cannot capture dynamic heterogeneity
The CSCH has been typically represented by a compartmental model of differentiation in which a stem cell, upon cell division,
becomes a TAC, which may divide a fixed number of times creating exact copies of itself, as a ‘progenitor’ cell, before
becoming a terminally differentiated cell (Fig. 2). Whether modeled using discrete, stochastic models like cellular automata38,
or through compartment based ordinary differential equations15 (ODEs), the conceptual framework is the same. In Figure 2,
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Figure 2. From a discrete, compartment-based description to a continuum. Left: The standard hierarchical stem cell
hypothesis, in which each cell type, i = (0,1,2), self-renews, differentiates and dies at rates ρi, βi and δi respectively. The
given ordinary differential equations thus describe the dynamics of each subpopulation. This rigid, unidirectional model has
been extended to various contexts such as dedifferentiation, but the discrete architecture has remained unchanged. Right: The
proposed Continuum Force Balance (CFB) model, which allows for a continuum of possible states along the clonogenic state
axis (c) which could govern a growth rate, ρ(c, t), incorporates flux of cells along the axis (Jc) as driven by microenvironmental
‘forces’ ( fi). TIC: Tumor Initiating Cell, TAC: Transit Amplifying Cell, TD: Terminally Differentiated cell.
we schematize a standard compartmental ODE model, in which a cancer stem cell, sometimes termed a Tumor Initiating Cell
(TIC, red) can divide symmetrically, to increase its own numbers, or asymetrically, to maintain TIC numbers and add one to
the downstream compartment of Transit Amplifying Cells (TACs). These TACs can then divide a certain number of times
before they reach senescence, and become Terminally Differentiated Cells (TDs). This simple model, and extensions of it,
have been used to study feedback control39,40, cancer therapy with chemotherapy15, as well as targeted therapy11,41, 42, and
hematopoesis43. Regardless of the utility, even basic aspects of this model, such as the number of divisions before progression
from one compartment to another, are currently experimentally inaccessible and can only be inferred theoretically44. Further, in
the standard CSCH, only TICs are clonogenic with high probability, but some extensions have allowed for de-differentiation of
TACs into TICs22 and even for terminally differentiated cells (TDs) to ‘move backward’ to become TACs23, though how this
would be controlled has not been determined.
We propose, instead, that each cell has some mean probability of clonogenicity that is a function of the extent to which
a cell is differentiated, which is, in turn, influenced by microenvironmental variables. We may conceptualize this change in
probability of clonogenicity as a cell becomes more differentiated as the cell traveling across a non-spatial dimension, which
we term the clonogenic state axis. A cell at the far “left” of this axis would be clonogenic with high probability (much like a
CSC in the canonical model), and a cell at the far “right” of the axis would be most likely unable to form a colony on its own (a
true TD). All other cells would have varying clonogenic potential dependent upon their position on this axis. Accounting for
this variance in probability of clonogenicity allows for unification of the original proliferative model and the CSCH and thereby
provides an explanation for the dichotomy between sphere-forming ability and true tumorigenicity between ‘marker positive’
cells45 and the phenotypic differences observed between spatially separated cells with the same stem marker status46.
To account for the plasticity that is observed in experiments perturbing the microenvironment31–33, we model the microenvi-
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ronmental variables that affect stemness as “forces” that direct a cell’s movement through the clonogenic state axis. This allows
for a single framework in which to view each of these otherwise disparate biological entities, and begs the question as to how
these forces are summed in space and time. These forces would, in healthy tissue, be slightly weighted towards the ‘right’ of
the axis, such that most cells differentiate as they divide. In a tumor, where there would be a pathologic microenvironment, this
balance would be disrupted to the ‘left’ in certain places, acting to skew the cellular population toward classical stemness: an
emergent CSC niche.
These different characteristics could account for inter-patient and intra-tumor heterogeneity, and also for the ‘stem cell
enrichment’ seen after certain therapies, to include radiation34, chemotherapy10,35 and certain microenvironmental factors,
such as hypoxia26, acidosis31, growth factors36, and even stromal cell cooperation/cooption32,33 (Table 1). Further, this concept
allows for a variable number of differentiation steps and cells of origin47–49, dependent on the ‘force balance’ inherent in the
environmental context.
Quantifying the effect of microenvironmental variables: a multidisciplinary task
The evolving CSCH has been driven by the growing body of literature suggesting that microenvironmental signals can affect
stemness (Table 1). We seek to coalesce these signals into a single ‘force’ term that will enable dynamic modeling of a spatially
heterogeneous hierarchically organized tumor with a continuum approximation. To do this in a way that is meaningful however,
will require adoption of this concept by experimental as well as theoretical scientists. Experiments which currently show the
qualitative effect of microenvironmental perturbations on ‘stemness’ must be done quantitatively, and a standard measure of
this ‘force’ will have to be ascribed. This measure of force must be descriptive enough to identify the change in the distribution
of a population of tumor cells from its initial state to a later state along the clonogenic state axis, and the time over which the
change occurred.
Table 1. Microenvironmental factors shown to increase stemness in the literature.
Factor Tissue type Source
Acidosis Glioblastoma Hjelmeland et al.31, Filatova et al.50
Hypoxia Glioblastoma Conley et al.26, Seidel et al.37, Soeda et al.51,
Griguer et al.52, Filatova et al.53, Kolenda et al.54
Radiation Breast and Glioblastoma Lagadec et al.25 and Tamura et al.34
Chemotherapy Glioblastoma and Liver Chen et al.10 and Hu et al.35
EGF Brain Doetsch et al.36
HGF and Wnt Colon Vermeulen et al.32
IL-6 and CXCL-7 Breast Liu et al.33
To coalesce the individual perturbations into a single measure, quantitative experiments focusing on dose-response
relationships using different ‘stem’ markers must be undertaken and scaling laws defined. Once this is accomplished,
experiments focusing on synergy between different factors can begin, and as each of the listed microenvironmental perturbations
identified so far is measured in different ways, the need for conversion factors arises. While understanding all possible
interactions would require many different combinations of the factors, even a minimal set of baseline quantitative experiments
would shed light on what is now only a qualitative understanding of the underlying biology. Once these baseline measurements
have been accomplished, the proposed model, along with continuum models of the microenvironment (e.g. Anderson et al.55),
could be used as a predictive tool to understand the temporal evolution of a clonogenic distribution and how it relates to factors
such as invasion, heterogeneity and treatment resistance.
To highlight the manner in which perturbations affect the distributions of clonogenic cells, experiments involving CD133
positive cells from a patient-derived xenograft cell line were assayed for SOX2 expression, as described in the Supplemental
Methods section. SOX2 is a transcription factor involved in the maintenance of the pluripotency of embryonic stem cells, and in
the experiments we present, serves as a marker of clonogenicity, with higher expression per cell corresponding to a ‘left’ shift
on the clonogenic state axis. Prior work has shown that silencing of SOX2 results in a significant decrease in clonogenicity,
underscoring its role as a critical measure of clonogenicity in a cell56.
In the experiments performed, we consider three different conditions of cell treatment, each of which shifts the distribution
of clonogenicity in unique ways. Cells are treated with either fetal bovine serum (FBS), a known differentiating agent for cancer
stem cells, epidermal growth factor (EGF) and FBS, or neurobasal media, with EGF and fibroblast growth factor (FGF). EGF,
as reported in Table 1 has been shown to induce stemness in neural precursors, and it is also thought that neurobasal media (the
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combination of FGF and EGF) should increase stemness as well, though we show that, in fact, these shift the distribution of
clonogenicity in distinct ways (Figure 3).
This dataset demonstrates how each force perturbs the distribution of cells over the clonogenic state axis in unique ways, and
how the forces are unique, in that they cannot be summed independently to obtain a combination distribution. Further, we note
that all cells at the beginning of the experiment were CD133 biomarker positive, suggesting that the gradient in clonogenicity
as elucidated by SOX2 expression varies significantly among this population.
Figure 3. Distribution of SOX2 fluorescence of cell populations grown in differing environments. Analogous to clonogenic
state distribution of population of cells, we see a large variation in the population distributions with shifts of the mean of
clonogenic potential to the right (corresponding to higher expression of SOX2).
Also, this suggests that binary classification by CD133 expression alone does not provide a significant degree of resolution
of the clonal capabilities of the cell population. In this vein, it is critical to note that the distribution of clonogenicity acts as a
hidden parameter in experimental data. That is, it is not directly observable with particular cellular surface markers used in a
binary manner, and in this way, may explain inconsistencies between populations of stem cells behaving vastly differently,
despite being similar in terms of biomarker positive proportion. In this sense, it may be that a biomarker selects only for
some subset of the distribution of clonogenic cells, but ignoring the intermediate clonogenicity of the cells not selected by the
biomarker may give rise to the discrepancies between the expected dynamics and the experimental observations.
Carcinogenesis and progression: from a static to dynamic understanding
As we continue to understand and classify the factors that exert these putative ‘forces’ which change the distribution of cells
along the clonogenic state axis, we will be better able to understand how the dysregulation of the force balance affects not only
tumor progression, but also carcinogenesis. For instance, it may be that pre-cancerous lesions are more ‘left-skewed’ than their
healthy counterparts, and that cancer-associated stroma is reacting in a physiologic manner to pathologic signals (‘left forces’).
Further, a loss of structure of distribution along the clonogenic axis, secondary to a perturbation or imbalance of the cellular
‘forces’, may define a cancerous tissue, or one which is changing from pre-malignant to malignant. Such a situation could be
reached by multiple combinations of genetic mutations or environmental perturbations in both the pre-malignant and healthy
associated tissue nearby. This provides a unification of the context-specific hypotheses of cancer that have plagued the CSCH
for so long, in which clonogenic cancer cells mixed with healthy tissue, may be affected by a physiologic ‘right force’, and
revert to a healthy state57.
By reformulating the CSCH with our continuum force balance (CFB) model, expressed mathematically as the partial
differential equation (PDE) in Fig. 2, we are also presented with novel opportunities to rethink the utility of cell surface markers
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previously attributed to ‘stemness’. We posit that the degree of positivity of a particular marker (applied in a binary fashion)
gives a measure of the proportion of the tumor population that exists to the left of a threshold on the clonogenic state axis. In
this sense, one may hypothesize that the use of thresholds from several markers in combination may give a strong sense of
the underlying distribution of the tumor cells along this axis. We argue that this distribution of clonogenicity is a more robust
measure of a tumor’s state, unmasking underlying complexity, than simply a proportion of CSCs with a single binary marker.
Importantly, this may provide the necessary explanation for the differences observed when reconstituting tumor populations
from ‘purified’ populations of biomarker-positive cell populations.
Spatial heterogeneity allows for the stem cell niche as an emergent phenomenon
To this point, we have offered a mathematical construct which describes the distribution of cancer cells along a continuous
‘clonogenic probability’ axis by means of a ‘clonogenic force’ based model, which we submit should replace the hierarchical
CSCH. We have described ways in which this new construct can better explain the existing biological observations and also
ways that it can open the field to new lines of questioning. Specifically, we have suggested novel methods to 1) quantitatively
define the effects of microenvironmental perturbations, 2) characterize the makeup of a tumor by utilizing suites of cell
surface markers, and 3) represent the effect of extrinsic microenvironmental pressures or genetic alterations as ‘forces’ along a
non-spatial continuum axis.
We emphasize that the equation described in Figure 2 (right) provides a concrete illustration of a more general framework
within which a continuum of clonogenicities may be incorporated. To better model the reality of spatial heterogeneity observed
in solid tumors, it is straight forward to extend this formulation to include physical space (x), thus,
net growth︷ ︸︸ ︷
ρ(c,x, t) =
total cells︷ ︸︸ ︷
∂n(c,x, t)
∂ t
+
net movement
along c-axis︷ ︸︸ ︷
∇c ·
(
Jc
)
+
net movement
in physical space︷ ︸︸ ︷
∇x ·
(
Jx
)
,
where Jc could be equal to n(c,x, t) f (c,x) or another functional form, and Jx can be represented by any appropriate function
modeling cell motility58. This addition allows for varying functions for birth, death and ‘forces’, both as the cell differentiates
(as a function of c), as a function of microenvironmental factors which would vary by physical location, x. The possibilities for
different functional forms for these fluxes (Jc and Jx) represents a rich field for both theoretical and experimental work. As
written, this formulation can now represent the stem cell niche as an emergent phenomenon secondary to microenvironmental
conditions and cellular characteristics; not unlike the current understanding of the hematopoietic stem cell niche59. It is worth
stressing that this ‘force’ term can include more than just soluble factors: by incorporating measurable perturbations from
cell-cell contact, interactions between different types of cells60, and even the current cell states, as modeled as the cell cylcle,
say. To understand the effects of these changes will require not just individual quantitative experiments, but also those done
in combination, as these effects need not sum up in a linear fashion. It is worth mentioning that the functional form of these
different perturbations may not be the same, and so our suggestion of a single term serves only as a beginning.
Another important benefit that we see is that we now offer a single mechanism to explain how different types of cancer stem
cell niches could be created and maintained (e.g. the perivascular61, invasive62, and hypoxic37 niches in glioblastoma). Further,
describing the tumor as a distribution of cells with varying ‘clonogenicity’ and state-specific replication and differentation rates,
rather than arbitrarily discretised compartments, we are able to model the changing nature of a tumor over time and space in a
new, quantitative, way.
Conclusion
The current state of modeling the CSCH has reached a point where there are a number of biological observations that challenge
assumptions in previous models, such as a continuity of stemness, plasticity of the stem phenotype and significant effects of the
physical microenvironment on stemness. To remedy this, we suggest revising this restrictive structure of the standard hierarchy
and offer instead a continuum force balance model, which allows for new quantitative observations to be interpreted in terms of
the clonogenic state force within a consistent mechanistic framework. This novel formulation serves to settle the dissonance
between the proliferative hypothesis and the CSCH and provides a single, integrated framework by which to capture several
puzzling phenomena in cancer biology. This description provides new opportunities for both theoretical and experimental
insights within the field of CSC research, which has presented many results but, to date, frustratingly few translatable insights.
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Supplementary Information
Experimental Methods
Glioblastoma stem cell preparation and maintenance in culture Human glioblastoma stem cells were enriched by CD133
Macs Beads (Miltenyi Biotech, San Diego, CA) following patient-derived xenograft tumor dissociation using the Papain
Dissociation System (Worthington Biocheical Co., Lakewood, NJ) as described previously63. They were maintained as sphere
cultures in Neurobasal medium supplemented with B27, L-glutamine, sodium pyruvate, penicillin, streptomycin (Thermofisher,
Waltham, MA), EGF and basic FGF (each at 20 ng/ml, R&D Systems, Minneapolis, MN).
Quantification of Sox2 expression To quantify Sox2 nuclear expression levels in individual cells, we used a quantitative
immunofluorescence approach as described previously64. To establish cancer stem cell monolayer cultures for immunostaining,
coverslip (22 × 22 mm, Thickness 1.5, Corning, NY) were coated with Geltrex (Thermofisher, Waltham, MA) as described
previously65. Geltrex, which is rich in laminin, was used as a cell attachment substrate to provide a stem-cell-supporting
environment66. Glioblastoma CSC spheres were dispersed to single cells with Accutase (Bioledgend, San Diego, CA) and
plated on to Geltrex coated coverslips in 6 well plates with CSC maintenance medium (200,000 cells per well). After 3 days of
culturing since changing the medium to one that contained either fetal bovine serum (FBS, 10%; Sigma-Aldrich, St. Louis,
MO), FBS & EGF (20 ng/ml), or EGF & FGF (20 ng/ml for each), the cells were fixed with 4% paraformaldehyde. Following
permeabilization and blocking with 0.1% (w/v) Triton X-100, 2% (v/v) normal donkey serum containing PBS, monolayers
were incubated with a specific antibody against Sox2 (1:500 dilution, mouse monoclonal (clone #245610) anti Sox2 antibody,
R&D Systems, Minneapolis, MN). Donkey anti mouse IgG conjugated with Cy3 (Jackson ImmunoResearch, West Grove, PA)
was used to detect bound anti Sox2 antibody, and DNA was stained with Hoechst 33342 (Polysciences Inc., Warrington, PA).
Digital images of Sox2 and DNA stainings of the same fields were taken using a fluorescent microscope (Leica DM5000B)
equipped with a digital camera (Leica DFC310FX).
Quantitative image analysis was performed using ImageJ64. Sox2 expression levels in individual nuclei were quantified by
integrating the pixel intensity values of Sox2 staining in the nuclear regions, which were defined by Hoechst staining.
7/10
Highlighted references
**Werner et al.11
In this paper, Werner et al. use a standard, compartment based ordinary differential equations model to show how the
dynamics of a leukemia under therapy can be used to identify the relative fraction of cancer stem cells. This highlights the
utility of the standard models in leukemia, and the clinical data analyzed shows how heterogeneous the parameters of a given
patient’s underlying system can be.
**Scott et al.45
Scott et al. show, using a stochastic agent based model of a tumor which grows obeying the standard hierarchy, that the
parameters of the model must be affected by the microenvironment to affect tumorigenicity. This result further highlights the
need for heterogeneity across cells within a solid tumor to reflect clinical reality.
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